Experience in treating drug-induced liver injury

L.V. Tarasova^1,2, O.L. Aryamkina^1,3, T.V. Volkova^1,3

¹Surgut State University, Surgut

²Chuvash State University named after I.N. Ulyanov, Cheboksary

³Surgut Regional Clinical Hospital, Surgut

Drug-induced liver injury (DILI) is one of the main adverse events of pharmacotherapy. New medicines appearance on the pharmaceutical market, the increase in the number of DILI caused by herbal preparations and dietary supplements, as well as the market expansion for immunobiological preparations, make medicines as the most important etiological factors of liver injury. The choice of tactics for the patient management with DILI is determined by the course and severity of the disease, the characteristics of the use of potentially hepatotoxic preparation, and the individual characteristics of the patient. There are common links in the DILI pathogenesis, including hypoxia, de-energization (deficit of ATP production), damage to hepatocyte membranes and inhibition of antioxidant protection. Therefore, pathogenetic pharmacotherapy and prevention of liver injury are based on preparations with a mechanism of acti on aimed at eliminating one or more links in the pathogenesis. One of these preparations is Remaxol, which includes antihypoxants and antioxidants of metabolic type: natural metabolites, substrates and cofactors involved in energy metabolism. The article presents the result of using Remaxol in a patient with drug-induced hepatotoxicity. The use of Remaxol made it possible to achieve clinical and biochemical remission, preventing the development of severe liver injury, and helped to preserve the recommended therapy duration of the underlying disease.

Keywords: drug-induced liver injury, hepatotoxicity, adverse events of pharmacotherapy, antioxidant, antihypoxant.

For citation: Tarasova L.V., Aryamkina O.L., Volkova T.V. Experience in treating drug-induced liver injury. RMJ. 2020;11:35–38.